Analyst Ratings for Ionis Pharmaceuticals (IONS) [Sells]
IONS Rating Summary
IONS Price Target Summary
- Highest: $70.00 (BMO Capital)
- Lowest: $26.00 (Goldman Sachs)
- Average: $47.53
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$47.53 (+21.1%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
Avg. $ Target:
$47.53 (+21.1%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/1/2022 | Citi » Updated 6/21/2022 |
David Lebowitz | New Coverage | Sell (N/A) |
26.00 (N/A) |
31.78 (39.25) |
23.51% | Details |
| 2/1/2022 | BofA Securities | Jason Gerberry | Downgrade | Underperform (Buy) |
30.00 (40.00) |
31.80 (39.25) |
23.43% | Details |
 |
||||||||
|
||||||||
IONS Ratings News
- AutoZone (AZO), Ionis Pharmaceuticals (IONS), and Thermo Fisher Scientific (TMO) Added to Citi Focus List. Four Names Removed
- Citi Reiterates Sell Rating on Ionis Pharmaceuticals (IONS), 'Limited Detail Keeps Us Weary on Competitive Profile', PT $26
- Stifel on Ionis Pharmaceuticals (IONS): 'we expect eplontersen to increase Ionis' share within the TTR space'
- See More
